On July 26, WAIC opened in Shanghai, and Tencent leaned in with a full-throated pitch. Its message centered on AI agents ...

Former chart toppers like Maoxiang and Talkie now see sharp user declines, weak monetization, and mounting regulatory ...

China Recap is a weekly roundup tracking Chinese companies expanding abroad, covering market entries, funding rounds, product ...

The US has reportedly frozen export controls on tech sales to China, including Nvidia’s H20 chip, to avoid disrupting trade talks and a potential meeting between national leaders. Security officials ...

Zhipu AI plans to release its largest open-source model, GLM-4.5, as early as July 28, joining a wave of Chinese firms accelerating open-source AI efforts, including Moonshot AI and StepFun. The ...

Hengrui Pharmaceuticals has licensed global rights to its HRS-9821 program and granted GSK options on up to 11 additional candidates, excluding Greater China. GSK will pay USD 500 million upfront, ...

Huawei executive Richard Yu has announced that the next-generation Aito M7 will launch in September. The redesigned model will offer both extended-range and all-electric variants, and will debut a new ...

Samsung Electronics has signed a USD 16.5 billion chip supply deal with a global client confirmed by Elon Musk to be Tesla, set to run through 2033. The agreement comes as Samsung faces pressure to ...

Laopu Gold has forecast H1 2025 sales of RMB 14.3 billion and adjusted net profit of RMB 2.36 billion, up 252% and 292% YoY, respectively. With operations across more than 30 malls, the company is ...

On July 28, Taobao Shangou and Ele.me announced that joint daily orders exceeded 90 million for two consecutive weekends, excluding zero-cost and self-pickup orders. Earlier in July, the platforms had ...

Alibaba has entered the smart glasses market with the debut of its "Quark AI" eyewear at WAIC 2025. Powered by Qualcomm’s AR1 chip, the glasses integrate with Alibaba apps including Alipay, Taobao, ...

Hengrui Pharmaceuticals has licensed global rights to its HRS-9821 program and granted GSK options on up to 11 additional candidates, excluding Greater China. GSK will pay USD 500 million upfront, ...